Precise Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GREENSBORO, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Precise Bio, Inc. (“Precise Bio” or the “Company”), a clinical-stage regenerative medicine company pioneering bio-printed tissues and organs with an initial focus on ophthalmology, today announced that Aryeh Batt, Co-Founder and Chief Executive Officer will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 25-26, 2026. The executive team will also be available for one-on-one meetings with investors throughout the conference.
Format: Company Presentation, Live Webcast
Date/Time: Thursday, February 26, 2026, at 8:00 am ET
About Precise Bio
Precise Bio is a clinical-stage regenerative medicine company pioneering tissue engineering using its proprietary 3D-bio-fabrication platform, which integrates cell biology and biomaterials to produce clinical-grade human tissues under GMP conditions. Its lead program, PB-001, is the world’s first bio-printed corneal implant to enter human clinical trials, with additional ophthalmology and advanced tissue programs in development. For more information, visit www.precise-bio.com.
Contact
Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
